OakChart

Skye Bioscience Inc

SKYEHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 8:26 AM ET

0.8994+0.0604 (7.20%)
2026-11-11 14:29 CET
Market cap
3.71 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-50.49 USD m
Free cash flow, TTM
-38.81 USD m
EPS diluted, TTM
-10.18
P/E
-
Compare

Price

SKYE against its 20, 50 and 200-day averages
2050200beatmiss
0.005.0010.00831K1.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SKYEclose 0.9020-day 1.3250-day 1.58200-day 4.580.90

93.1% under 12.96 on 31 Oct 2025. Last 15 sessions, 230.0% high to low

Profile

SKYE
52-week range, 3% of the way up
0.5012.72

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the business of research and development activities related to developing medicine for obesity and metabolic diseases. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

Employees12
IPONov 26, 2014
Beta3.19
ATR, 14d0.17
Rel volume1.64
Short float4.34%
Insider own32.76%
Inst own18.32%

Snapshot

6 groups

Valuation

Index-
Market Cap3.98M
Enterprise Value-5.90M
Income-50.49M
Sales0.00M
Book/sh-0.11
Cash/sh2.28
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees12
IPONov 26, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C0.40
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.95
Current Ratio0.95
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-10.18
EPS next Y-6.75
EPS next Q-1.14
EPS this Y47.52%
EPS next Y-13.96%
EPS next 5Y1.68%
EPS past 3/5Y45.62% 28.34%
Sales past 3/5Y- -
EPS Y/Y TTM-19.07%
Sales Y/Y TTM-
EPS Q/Q38.85%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.-13.30% -

Ownership

Insider Own32.76%
Insider Trans-43.44%
Inst Own18.32%
Inst Trans6.56%
ROA-159.80%
ROE-233.87%
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-31.73%
SMA50-43.07%
SMA200-80.35%
Trades-

Technical

Shs Outstand4.39M
Shs Float2.98M
Short Float4.34%
Short Ratio1.11
Short Interest0.13M
52W High12.72 -92.93%
52W Low0.50 79.84%
Volatility36.29% 14.89%
ATR (14)0.17
RSI (14)31.06
Beta3.19
Rel Volume1.64
Avg Volume116.29K
Volume9,525

Performance

Perf Week-21.11%
Perf Month-41.22%
Perf Quarter-79.22%
Perf Half Y-86.28%
Perf YTD-85.00%
Perf Year-92.30%
Perf 3Y-93.39%
Perf 5Y-99.33%
Perf 10Y-99.90%
Recom3.00
Target Price16.00
Prev Close0.84
Price0.90
Change %7.20%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Oct 06, 2025DowngradeCCraig HallumBuy → Hold$2+122.4%
Oct 06, 2025DowngradeCCantor FitzgeraldOverweight → Neutral$2+122.4%
Aug 15, 2025InitiatedEEvercore ISIOutperform$10+1,011.9%
Feb 28, 2025InitiatedWWilliam BlairOutperform
Sep 30, 2024InitiatedBScotiabankSector Outperform$20+2,123.7%
Sep 10, 2024InitiatedJJMP SecuritiesMkt Outperform$15+1,567.8%
Jul 09, 2024InitiatedCCraig HallumBuy$18+1,901.3%
May 23, 2024InitiatedCCantor FitzgeraldOverweight$21+2,234.9%
Apr 12, 2024InitiatedOOppenheimerOutperform$25+2,679.6%

Peers

Mkt cap
TickerCompanyMkt cap
TVRDTvardi Therapeutics Inc18.54M
GYREGyre Therapeutics Inc487.81M
PLRXPliant Therapeutics Inc48.65M
AVLNAvalyn Pharma Inc1.38B
RNTXRein Therapeutics Inc50.90M
GALTGalectin Therapeutics Inc352.97M
VCREVicore Pharma Holding AB ADR319.62M
FBLGFibroBiologics Inc6.15M
IVAInventiva ADR915.75M
SVRASavara Inc1.11B

Insider trading

12 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Schwab Andrew J.DirectorSep 23 '26Sale1.61119,379192,2000Sep 24 04:31 PM
Schwab Andrew J.DirectorSep 22 '26Sale1.6528,70047,3554,528Sep 24 04:31 PM
5AM Partners VII, LLC10% OwnerSep 23 '26Sale1.61119,379192,2000Sep 24 04:29 PM
5AM Partners VII, LLC10% OwnerSep 22 '26Sale1.6528,70047,3554,528Sep 24 04:29 PM
Schwab Andrew J.DirectorSep 16 '26Sale1.9133,89264,7345,616Sep 18 06:39 PM
5AM Partners VII, LLC10% OwnerSep 16 '26Sale1.9133,89264,7345,616Sep 18 06:37 PM
Schwab Andrew J.DirectorAug 18 '26Sale0.38300,000114,00055,663Aug 20 05:59 PM
Schwab Andrew J.DirectorAug 19 '26Sale0.3568,14023,84955,254Aug 20 05:59 PM
Schwab Andrew J.DirectorAug 20 '26Sale0.327,7002,46455,208Aug 20 05:59 PM
5AM Partners VII, LLC10% OwnerAug 18 '26Sale0.38300,000114,00055,663Aug 20 05:57 PM
5AM Partners VII, LLC10% OwnerAug 19 '26Sale0.3568,14023,84955,254Aug 20 05:57 PM
5AM Partners VII, LLC10% OwnerAug 20 '26Sale0.327,7002,46455,208Aug 20 05:57 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.61B
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B

News

latest 14 of 206
  • Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Fibrex ... (GuruFocus.com) -17.23%
  • Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings (GlobeNewswire) -7.30%
  • The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea (Yahoo Finance)
  • Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 (GlobeNewswire) +6.04%
  • UPDATE - Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update (GlobeNewswire) -7.56%
  • Loading…
  • Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update (GlobeNewswire)
  • Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit (GlobeNewswire)
  • Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development (GlobeNewswire)
  • Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ... (GuruFocus.com) -9.70%
  • Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) +10.33%
  • Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 (GlobeNewswire)
  • Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year (Benzinga) -7.92%
  • Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-2.160-1.906-2.1600.000.006
2026Q12026-05-11-2.560-2.468-2.5220.000.007
2025Q42026-03-10-2.880-2.377-2.9120.000.007
2025Q32025-11-10-2.560-2.510-2.5720.000.008
2025Q22025-08-07-3.520-2.560-3.5550.000.006
2025Q12025-05-08-2.240-2.296-2.2400.000.006
2024Q42025-03-20-1.920-2.227-1.9510.000.007
2024Q32024-11-07-0.800-1.995-0.8030.000.006
2024Q22024-08-09-1.600-1.560-1.6350.000.004
2024Q12024-05-29-1.440-1.385-1.4340.000.003
2023Q42024-02-28-3.816-3.040-2.8630.000.001
2026Q3---1.142--0.003
2026Q4---1.058--0.003
2027Q1---1.588--0.003
2027Q2---1.578--0.003
2027Q3---1.726--0.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-42.969-43.440-42.9860.000.00
2024FY-5.840-6.889-5.8250.000.00
2025FY-11.280-11.115-11.2800.000.00
2026FY--5.920--0.00
2027FY--6.747--0.00
2028FY--10.722---
2029FY--12.560---
2030FY--4.480--86.90

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-282000.000.000.00
2026Q3S2026-08-273000.000.000.00
2026Q3S2026-08-204000.000.000.00
2026Q3S2026-08-145000.000.000.00
2026Q3S2026-05-126000.000.000.00
2026Q3S2026-03-116000.000.000.00
2026Q3S2025-11-116000.000.000.00
2026Q3S2025-11-105000.000.000.00
2026Q3S2025-11-095000.000.000.00
2026Q3S2025-11-085000.000.000.00
2026Q3S2025-11-075000.000.000.00
2026Q3S2025-11-065000.000.000.00
2026Q3S2025-11-055000.000.000.00
2026Q3S2025-11-045000.000.000.00

Estimate history

EPS, annual-296.58-316.86-96.7-59.68-41.92-70.16-42.986-5.825-11.28-10.1804
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.635-0.803-1.951-2.24-3.555-2.572-2.912-2.522-2.174
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0170.0670.0910.1440.2380.4571.5443.8724.1724.393
Period201720182019202020212022202320242025MRQ
Shares, quarterly3.5083.7923.8723.8723.8743.8744.1724.3914.393
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.690.720.300.120.110.030.000.000.00
Gross Profit-0.69-0.72-0.30-0.12-0.11-0.03-0.00-0.00-0.00
Selling, General and Administrative Excl. Other47.9657.4436.1313.5511.997.816.296.634.69
Research and Development32.0241.6418.705.825.902.901.942.240.33
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-48.65-58.16-36.43-13.67-12.11-7.85-6.29-6.63-4.69
Interest Expense0.010.000.750.910.790.770.711.000.23
Unusual Expense3.250.00-6.2322.866.60-0.10-0.44-8.6914.27
Net Income Before Taxes-50.49-55.92-26.56-37.64-19.47-8.52-6.561.05-19.19
Income Taxes0.000.010.010.000.010.000.000.000.00
Consolidated Net Income-50.49-55.92-26.57-37.64-19.48-8.52-6.561.05-19.19
Net Income From Continuing Operations-50.49-55.92-26.57-37.64-19.48-8.52-6.561.05-19.19
Net Income-50.49-55.92-26.57-37.64-19.48-8.52-6.561.05-19.19
EPS (Recurring)-9.72-11.28-6.78-24.72-53.52-42.25-62.32-168.43-151.98
EPS (Basic, Before Extraordinaries)-10.18-11.28-5.83-42.99-70.16-41.92-56.8615.56-316.86
EPS (Diluted)-10.18-11.28-5.83-42.99-70.16-41.92-59.68-96.70-316.86
EBITDA-47.96-57.44-36.13-13.55-11.99-7.81-6.29-6.63-4.69
Non-Operating Income (Expense)1.412.244.38-0.210.023E-060.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.696.146.570.780.500.630.220.500.53
Shares Outstanding4.394.173.871.540.460.240.140.090.07
Market Capitalization3.713.7187.6633.568.0324.7611.5223.8753.56

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.160.170.180.180.190.180.180.07
Gross Profit-0.16-0.17-0.18-0.18-0.19-0.18-0.18-0.07
Selling, General and Administrative Excl. Other7.6512.5014.7213.0918.0611.5812.179.46
Research and Development3.787.7611.299.1814.157.027.794.88
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.81-12.67-14.90-13.26-18.24-11.76-12.35-9.52
Interest Expense0.000.000.000.000.000.00--
Unusual Expense3.250.000.000.000.000.00-1.68-4.55
Net Income Before Taxes-10.78-12.51-14.44-12.75-17.62-11.10-9.75-3.90
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-10.79-12.51-14.44-12.75-17.62-11.10-9.75-3.90
Net Income From Continuing Operations-10.79-12.51-14.44-12.75-17.62-11.10-9.75-3.90
Net Income-10.79-12.51-14.44-12.75-17.62-11.10-9.75-3.90
EPS (Recurring)-1.72-2.52-2.91-2.57-3.56-2.24-2.19-1.46
EPS (Basic, Before Extraordinaries)-2.17-2.52-2.91-2.57-3.56-2.24-1.95-0.80
EPS (Diluted)-2.17-2.52-2.91-2.57-3.56-2.24-1.95-0.80
EBITDA-7.65-12.50-14.72-13.09-18.06-11.58-12.17-9.46
Non-Operating Income (Expense)0.280.170.450.510.620.660.921.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.001.501.281.911.611.741.651.92
Shares Outstanding4.394.394.173.873.873.873.873.79
Market Capitalization3.7121.5925.02121.79129.5349.2587.66118.62

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments25.7468.4210.341.258.992.471.831.860.26
Short Term Receivables0.010.010.030.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.352.411.287.690.620.190.160.100.29
Total Current Assets27.0970.8311.658.949.612.661.991.950.56
Net Property, Plant & Equipment1.171.880.280.160.230.010.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets---0.000.000.000.000.000.00
Other Assets0.050.050.010.010.010.000.000.000.00
Total Assets28.3172.7611.949.119.862.672.001.960.56
Short Term Debt Incl. Current Port. of LT Debt0.190.184.441.932.060.060.000.000.23
Accounts Payable2.030.571.161.790.900.380.140.020.10
Other Current Liabilities5.983.598.308.400.950.340.8315.920.47
Total Current Liabilities8.214.3413.9012.123.910.790.9715.940.81
Long Term Debt0.080.270.170.000.081.430.391.360.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.090.220.55
Total Liabilities8.294.6114.0712.123.992.221.4517.521.36
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.002.77
Common Equity20.0268.15-2.13-3.015.860.450.55-15.56-3.57
Total Shareholders Equity20.0268.15-2.13-3.015.860.450.55-15.56-0.80
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity20.0268.15-2.13-3.015.860.450.55-15.56-0.80
Total Liabilities & Stockholders Equity28.3172.7611.949.119.862.672.001.960.56
Book Value Per Share4.8017.60-1.38-6.5924.633.135.99-232.43-212.33
Tangible Book Value Per Share4.8017.60-1.38-6.5924.633.135.99-232.43-212.33
Full-Time Employees1216111196433
Price to Book Ratio-7.411.2919.80-2.454.2225.5643.55-3.44-1.44
Return on Assets-110.66-62.73-357.64-205.44-136.06-281.0653.20-1,526.78-702.79
Return on Equity-126.85-80.48--1,364.20-269.90-1,313.66---
Return on Invested Capital-278.12-38.83---143.40-348.14112.48--
Quick Ratio3.3016.320.840.742.463.382.050.120.69
Current Ratio3.3016.320.840.742.463.382.050.120.69

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-50.49-55.92-26.57-37.64-19.48-8.52-6.561.05-19.19
Depreciation0.690.720.300.120.110.030.000.000.00
Other Funds (Non Cash)9.707.413.6624.047.381.370.41-7.3815.15
Funds from Operations-40.10-47.79-22.61-13.48-11.98-7.12-6.15-6.32-4.04
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.294.73-2.63-0.47-0.760.650.090.300.10
Cash from Operating Activities-38.81-43.06-25.24-13.95-12.74-6.47-6.05-6.03-3.94
Capital Expenditures0.00-0.01-1.60-0.01-0.03-0.09-0.010.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.090.000.001.085.310.000.000.00-
Purchase or Sale of Investments23.11-19.491.365.530.000.000.000.000.00
Purchase of Investments4.89-19.850.000.000.000.000.000.000.00
Sale Or Maturity of Investments18.220.361.365.530.000.000.000.000.00
Other Uses0.000.000.000.00-0.070.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities23.20-19.50-0.256.605.21-0.09-0.010.00-0.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.020.0383.5611.730.0013.086.136.000.10
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.020.0383.5611.730.0013.086.136.000.10
Proceedsfrom Stock Options0.020.030.0111.730.006.066.091.920.00
Issuance or Reduction of Debt, Net-0.180.000.004.71-0.210.000.570.012.35
Change in Long Term Debt0.000.000.00-0.26-0.210.000.570.011.95
Issuance of Long Term Debt0.000.000.000.000.680.000.573.991.95
Reduction of Long Term Debt0.000.000.00-0.26-0.890.000.00-3.990.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.003.10
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-0.160.0383.5616.44-0.2113.086.706.005.54
Net Change in Cash-15.77-62.5358.089.09-7.746.510.64-0.021.59
Free Cash Flow-38.81-43.07-26.84-13.96-12.77-6.57-6.06-6.03-3.95
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments10.0617.1125.7435.3148.5959.22
Short Term Receivables0.010.010.010.020.010.01
Inventories0.000.000.000.000.000.00
Other Current Assets0.891.451.354.601.983.80
Total Current Assets10.9618.5727.0939.9250.5863.03
Net Property, Plant & Equipment0.070.811.171.351.521.71
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.010.040.050.050.050.05
Total Assets11.0319.4228.3141.3252.1664.79
Short Term Debt Incl. Current Port. of LT Debt0.180.310.190.200.200.19
Accounts Payable4.283.942.032.833.221.71
Other Current Liabilities7.076.165.985.344.893.42
Total Current Liabilities11.5310.408.218.378.315.32
Long Term Debt0.000.000.080.120.170.22
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities11.5310.408.298.498.485.54
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-0.509.0120.0232.8443.6859.25
Total Shareholders Equity-0.509.0120.0232.8443.6859.25
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-0.509.0120.0232.8443.6859.25
Total Liabilities & Stockholders Equity11.0319.4228.3141.3252.1664.79
Book Value Per Share-0.112.054.808.4811.2815.30
Tangible Book Value Per Share-0.112.054.808.4811.2815.30
Full-Time Employees--12---
Price to Book Ratio-7.412.401.253.712.970.83
Return on Assets-159.80-136.16-110.66-83.39-60.78-40.91
Return on Equity-233.87-167.97-126.85-94.31-72.75-47.27
Return on Invested Capital--138.81-71.82-38.70-40.19-18.67
Quick Ratio0.951.783.304.776.0911.85
Current Ratio0.951.783.304.776.0911.85

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-10.79-12.51-14.44-12.75-17.62-11.10
Depreciation0.160.170.180.180.190.18
Other Funds (Non Cash)4.931.501.441.821.942.20
Funds from Operations-5.70-10.83-12.82-10.75-15.49-8.72
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.432.273.06-2.614.75-0.46
Cash from Operating Activities-7.12-8.56-9.77-13.36-10.75-9.19
Capital Expenditures0.000.000.000.000.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.180.00-0.180.090.090.00
Purchase or Sale of Investments6.9610.90-2.627.88-11.94-12.80
Purchase of Investments0.000.00-2.987.88-11.94-12.80
Sale Or Maturity of Investments6.9610.900.360.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.1410.90-2.807.97-11.86-12.81
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.010.000.010.000.020.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.010.000.010.000.020.00
Proceedsfrom Stock Options0.010.000.010.000.020.00
Issuance or Reduction of Debt, Net-0.11-0.070.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.10-0.070.010.000.020.00
Net Change in Cash-0.082.27-12.56-5.40-22.58-21.99
Free Cash Flow-7.12-8.56-9.77-13.36-10.75-9.19

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.34%0.1M3.0M89.96K
2026-10-154.71%0.1M3.0M88.57K
2026-09-304.96%0.1M3.0M87.56K
2026-09-154.18%0.1M2.8M76.53K
2026-08-314.63%0.1M2.8M66.06K
2026-08-145.49%0.2M2.7M31.77K
2026-07-315.73%0.2M2.9M19.26K
2026-07-154.59%0.1M2.9M22.50K
2026-06-304.14%0.1M2.9M23.87K
2026-06-154.24%0.1M2.9M26.11K
2026-05-294.91%0.1M2.9M63.17K
2026-05-155.52%0.2M2.9M63.88K
2026-04-305.76%0.2M2.8M69.49K
2026-04-156.54%0.2M2.8M68.54K
2026-03-317.72%0.2M2.6M74.91K
2026-03-137.60%0.2M2.6M85.86K
2026-02-274.87%0.1M2.5M48.08K
2026-02-134.63%0.1M2.5M49.41K
2026-01-305.11%0.1M2.5M47.18K
2026-01-154.80%0.1M2.5M55.68K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-28PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-26PREM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-26SEC
2026-10-14SCHEDULE 13GSEC
2026-09-24SCHEDULE 13D/ASEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-11DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-118-KCurrent report2026-09-08SEC
2026-08-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-248-KCurrent report2026-08-21SEC
2026-08-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-208-K/A2026-08-12SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-19DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-198-KCurrent report2026-08-18SEC
2026-08-18SCHEDULE 13D/ASEC
2026-08-14DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-12SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-06-238-KCurrent report2026-06-18SEC
2026-05-298-KCurrent report2026-05-26SEC
2026-05-158-KCurrent report2026-05-13SEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-283Initial statement of beneficial ownership of securities2026-03-31SEC
2026-04-16ARSAnnual report to security holders. 2025-12-31SEC
2026-04-16DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900608.58K6
2026-0800280.63K6
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
5AM Venture Management, LLC27.55%
Versant Venture Management, LLC5.71%
BAKER BROS. ADVISORS LP4.48%
VANGUARD CAPITAL MANAGEMENT LLC2.17%
SPHERA FUNDS MANAGEMENT LTD.1.93%
UBS Group AG0.91%
PLATINUM INVESTMENT MANAGEMENT LTD0.66%
BlackRock, Inc.0.66%
GEODE CAPITAL MANAGEMENT, LLC0.62%
MILLENNIUM MANAGEMENT LLC0.56%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.60%
VANGUARD EXTENDED MARKET INDEX FUND0.53%
Fidelity Extended Market Index Fund0.31%
Fidelity Total Market Index Fund0.09%
Fidelity Series Total Market Index Fund0.07%
VANGUARD BALANCED INDEX FUND0.05%
Fidelity Nasdaq Composite Index Fund0.03%

OakChart. SKYE. Cached 15 minutes.